Cash and cash equivalents were $5.6 million as of June 30, 2024.”We made significant progress in advancing our three development programs year-to-date, with a particular focus on our lead candidate NGC-Cap,” said George Ng, Chief Executive Officer of Processa Pharmaceuticals. “Upon receiving FDA clearance of our NGC-Cap IND application, we initiated a Phase 2 clinical trial in metastatic breast cancer. We look forward to enrolling patients in this multicenter, open-label study and expect to have an initial data readout in mid-2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCSA:
- Processa Pharmaceuticals announces preclinical data for NGC-Iri
- Processa Pharmaceuticals price target lowered to $6 from $8 at H.C. Wainwright
- 3 Penny Stocks to Watch Now, 8/1/24
- Processa Pharmaceuticals announces FDA clearance of IND application for NGC-Cap
- Processa Pharmaceuticals Welcomes New CFO Russell Skibsted